DISCOVER-HCM

DISCOVER-HCM

DELIVER INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY AND OBSERVATIONAL OUTCOMES IN REAL WORLD (DISCOVER-HCM): UNITED STATES PROSPECTIVE REGISTRY STUDY

To evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) in the real-world setting. The registry evaluates patient characteristics, real-world treatment patterns and short- and long-term outcomes in a population of patients with symptomatic obstructive HCM who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.

Please use this link for further information:
clinicaltrials.gov


Primary Investigator: Wojciech Mazur